Introduction/Background Ovarian cancer presents a significant challenge in gynecologic oncology, spurring exploration of innovative strategies like Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This study evaluates the real-world impact of introducing HIPEC by comparing outcomes before and after its incorporation into interval cytoreduction.

Methodology Retrospective analysis covered a prospective ovarian cancer database from a tertiary referral center. Inclusion criteria comprised patients undergoing interval CRS for advanced ovarian cancer from 2012 to 2022. Comprehensive analysis of epidemiological and clinical data was conducted.

Results Results indicate that among the 179 patients undergoing interval CRS, 86 were in the non-HIPEC arm and 93 in the CRS and HIPEC arm. Non-HIPEC patients exhibited significantly lower median overall survival (OS) at 44.7 months (p<0.05), compared to 57.7 months in the HIPEC arm. The median progression-free survival 1 (PFS1) for the entire cohort was 18.8 months, with 21.3 months in the HIPEC arm and 15.2 months in the non-HIPEC arm (p=0.1). Excluding stage IV cases revealed a significant PFS1 difference (p<0.05) between non-HIPEC (60 months) and HIPEC (85 months) groups.

Multivariate analysis demonstrated HIPEC’s protective effect in OS (HR 0.58, p<0.05 for all patients; HR 0.543, p<0.05 for stage III cases). For PFS1, significant factors included the number of anastomoses (HR 1.579, p<0.05 for >1 anastomosis; HR 1.904, p<0.05 for >3). In stage III cases, HIPEC emerged as the sole protective variable (HR 0.665, p<0.05). In PFS2, the overall population exhibited a detrimental impact of maintenance treatment (HR 2.1, p<0.05), while HIPEC demonstrated a protective effect (HR 0.58, p<0.05).

Conclusion Our findings highlight HIPEC’s transformative impact in the cytoreductive landscape of ovarian cancer, emphasizing the need for its thoughtful integration into therapeutic protocols. Further research is crucial to refine treatment protocols for enhanced efficacy in managing ovarian cancer of ovarian origin.

Disclosures No disclosures.